C

Centro Respiratorio Quilmes | Buenos Aires, Argentina

Research site

(Unclaimed)

Location

Yrigoyen 856, Quilmes, Buenos Aires, Argentina

Site insights

Top conditions

Top treatments

Lebrikizumab

Astegolimab

MTPS9579A

CHF5993

AP01

BAY1817080

Povorcitinib

JNJ-53718678

SUN11031

Bexotegrast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 14 total trials

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus pla...

Active, not recruiting

Pulmonary Fibrosis Secondary to Systemic Sclerosis

Pulmonary Fibrosis

Drug: AP01

Other: Placebo

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling

Moderate to Severe Asthma

Drug: ICS-LABA

Other: placebo

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling

Chronic Obstructive Pulmonary Disease

Drug: Astegolimab

Locations recently updated

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (TRECONY)

This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. W...

Enrolling

Asthma

Drug: CHF5993 pMDI with HFA-134a

Drug: CHF5993 pMDI with HFA-152a